Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772305 | 1.00 | PTGS2 (0.53) | PTGS2AKR1C2AKR1C1AKR1C3ESR2 | |
| SCHEMBL7619212 | 0.85 | SRD5A2 (0.56) | AKR1C3GSRKMT2A | |
| SCHEMBL6180942 | 0.85 | NPC1 (0.63) | PTGS2AKR1C3GSRKMT2APAX8 | |
| SCHEMBL8385173 | 0.84 | KMT2A (0.52) | PTGS2AKR1C2AKR1C1AKR1C3KMT2A | |
| SCHEMBL6201900 | 0.84 | RAB9A (0.59) | — | |
| SCHEMBL6024972 | 0.84 | CA2 (0.62) | — | |
| SCHEMBL6341279 | 0.83 | PTGS2 (0.51) | PTGS2AKR1C2AKR1C1GSR | |
| SCHEMBL8602859 | 0.83 | MAPT (0.59) | PTGS2AKR1C3GSR | |
| SCHEMBL6999652 | 0.82 | AKR1C3 (0.52) | PTGS2AKR1C3GSRKMT2A | |
| SCHEMBL7625358 | 0.81 | CA12 (0.52) | PTGS2GSRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518303-B2 | Selectively inhibit COX-2 in preference to COX-1 and are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects | ALMIRALL PRODESFARMA S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| EP-1115716-B1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | LABORATORIES ALMIRALL, S.A. (ES) | 2002-04-18 | — | — | US | disclosed |
| US-6329421-B1 | PHENYL-SUBSTITUTED BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES; NONSTEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-12-11 | — | — | US | disclosed |
| EP-0778834-B1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2000-01-26 | — | — | EP | disclosed |
| EP-0778834-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1997-06-18 | — | — | EP | disclosed |
| US-5521213-A | NONSTEROID ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-05-28 | — | — | US | disclosed |
| WO-1996006840-A1 | DIARYL BICYCLIC HETEROCYCLES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | NR4A1, CYP3A4, HTR4 | PTGS2 912/4885AKR1C2 710/4885AKR1C1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.